<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988646</url>
  </required_header>
  <id_info>
    <org_study_id>515/STD/PML/2019</org_study_id>
    <nct_id>NCT04988646</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject</brief_title>
  <official_title>Pharmacokinetic Properties of Acyclovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT. Kimia Farma (Persero) Tbk</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PT Pharma Metric Labs</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PT. Kimia Farma (Persero) Tbk</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this present study was to asses the pharmacokinetic properties of acyclovir&#xD;
      tablet from new product formulation (PT. Kimia Farma (Persero) Tbk) to its innovator product,&#xD;
      Zovirax® tablet (Glaxo Wellcome S.A., Aranda, Spain)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty-eight healty subjects were given a single dose of acyclovir tablet or Zovirax® in&#xD;
      dosage form 200 mg and 400mg with 240 mL of water. Then the blood samples for acyclovir was&#xD;
      drawn and analyzed using LCMS/MS. All subjects sample plasma were analyzed for&#xD;
      pharmacokinetic evaluation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Actual">April 28, 2020</completion_date>
  <primary_completion_date type="Actual">April 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, single blind, single dose, 2-periods, cross-over design study with one week washout period between each treatment in 28 healthy subjects under fasting condition</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameter</measure>
    <time_frame>From 0 to 24 hours</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameter</measure>
    <time_frame>Predose at (0 h) and 15, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours post dose</time_frame>
    <description>Area Under Curve from 0 to 24 hours (AUCt)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio</measure>
    <time_frame>From 0 to 24 hours</time_frame>
    <description>The ratio between test drug and reference drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90% confidence intervals</measure>
    <time_frame>From 0 to 24 hours</time_frame>
    <description>The two products are considered bioequivalent when the 90% confidence intervals of the Acyclovir and Zovirax® tablet geometric mean ratio between test and reference product fall within the range of 80.00-125.00% for AUCt and Cmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Drug Use</condition>
  <arm_group>
    <arm_group_label>Acyclovir Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Acyclovir Tablet 200 mg or 400 mg with 240 mL of water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zovirax® Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Zovirax® Tablet 200 mg or 2x200 mg with 240 mL of water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir 200 MG</intervention_name>
    <description>Administered with 240 mL of water</description>
    <arm_group_label>Acyclovir Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir 400 MG</intervention_name>
    <description>Administered with 240 mL of water</description>
    <arm_group_label>Acyclovir Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zovirax 200 MG Tablet</intervention_name>
    <description>Administered with 240 mL of water</description>
    <arm_group_label>Zovirax® Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zovirax 400 MG Tablet</intervention_name>
    <description>Administered with 240 mL of water</description>
    <arm_group_label>Zovirax® Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  body weight within normal range (body mass index between 18 and 25 kg/m2)&#xD;
&#xD;
          -  had normal blood pressure (systolic was ranged between 90 to 120 mmHg and diastolic&#xD;
             was ranged between 60 to 80 mmHg)&#xD;
&#xD;
          -  had normal electrocardiogram&#xD;
&#xD;
          -  absence of significant disease or clinically significant abnormal laboratory values on&#xD;
             laboratory evaluation, medical history or physical examination during screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  nursing mothers&#xD;
&#xD;
          -  women of childbearing potential without adequate contraception&#xD;
&#xD;
          -  had a history of contraindication or hypersensitivity to aciclovir, or other antiviral&#xD;
             or other ingredients in the study products or a history of serious allergic reaction&#xD;
             to any drug,&#xD;
&#xD;
          -  a significant allergic disease, or allergic reaction; presence of medical condition&#xD;
             which might significantly influence the pharmacokinetics of the study drug, e.g.&#xD;
             chronic gastrointestinal disease, diarrhea, gastric surgery, renal insufficiency,&#xD;
             hepatic dysfunction or cardiovascular disease&#xD;
&#xD;
          -  presence of any coagulation disorder or clinically significant hematology&#xD;
             abnormalities; using any medication (prescription or non-prescription drug, food&#xD;
             supplement, herbal medicine)&#xD;
&#xD;
          -  particularly the medication known to affect the pharmacokinetics of the study drug&#xD;
&#xD;
          -  who had participated in any clinical study within 3 months prior to the study (&lt; 90&#xD;
             days)&#xD;
&#xD;
          -  subjects who had donated or lost 300 ml (or more) of blood within 3 months prior to&#xD;
             the study&#xD;
&#xD;
          -  who were positive to HIV, HBsAg, and HCV tests&#xD;
&#xD;
          -  who were unlikely to comply with the protocol, e.g uncooperative attitude, inability&#xD;
             to return for follow up visits&#xD;
&#xD;
          -  poor venous access; and who smoked more than 10 cigarettes a day&#xD;
&#xD;
          -  had a history of drug or alcohol abuse within 12 months prior to screening for this&#xD;
             study and who were unlikely to comply with the protocol, e.g uncooperative attitude,&#xD;
             inability to return for follow up visits, poor venous access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Metta Sinta Sari Wiria</last_name>
    <role>Principal Investigator</role>
    <affiliation>PT Pharma Metric Labs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>I Gusti Putu Bagus Diana Virgo</last_name>
    <role>Study Director</role>
    <affiliation>PT Pharma Metric Labs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PT Pharma Metric Labs</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10520</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <results_reference>
    <citation>Stahl JP, Mailles A. Herpes simplex virus encephalitis update. Curr Opin Infect Dis. 2019 Jun;32(3):239-243. doi: 10.1097/QCO.0000000000000554. Review.</citation>
    <PMID>30921087</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahronowitz I, Fox LP. Herpes zoster in hospitalized adults: Practice gaps, new evidence, and remaining questions. J Am Acad Dermatol. 2018 Jan;78(1):223-230.e3. doi: 10.1016/j.jaad.2017.07.054. Epub 2017 Nov 14. Review.</citation>
    <PMID>29146146</PMID>
  </results_reference>
  <results_reference>
    <citation>Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: life cycle and development of inhibitors. Biochemistry (Mosc). 2014 Dec;79(13):1635-52. doi: 10.1134/S0006297914130124. Review.</citation>
    <PMID>25749169</PMID>
  </results_reference>
  <results_reference>
    <citation>Vaithianathan S, Haidar SH, Zhang X, Jiang W, Avon C, Dowling TC, Shao C, Kane M, Hoag SW, Flasar MH, Ting TY, Polli JE. Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. J Pharm Sci. 2016 Feb;105(2):996-1005. doi: 10.1002/jps.24643. Epub 2016 Jan 12.</citation>
    <PMID>26375604</PMID>
  </results_reference>
  <results_reference>
    <citation>de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983 Sep;12 Suppl B:29-37. Review.</citation>
    <PMID>6355048</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989 Mar;37(3):233-309. Review.</citation>
    <PMID>2653790</PMID>
  </results_reference>
  <results_reference>
    <citation>Fletcher C, Bean B. Evaluation of oral acyclovir therapy. Drug Intell Clin Pharm. 1985 Jul-Aug;19(7-8):518-24. Review.</citation>
    <PMID>2992899</PMID>
  </results_reference>
  <results_reference>
    <citation>Al-Yamani MJ, Al-Khamis KI, El-Sayed YM, Bawazir SA, Al-Rashood KA, Gouda MW. Comparative bioavailability of two tablet formulations of acyclovir in healthy volunteers. Int J Clin Pharmacol Ther. 1998 Apr;36(4):222-6.</citation>
    <PMID>9587049</PMID>
  </results_reference>
  <results_reference>
    <citation>Amini H, Javan M, Gazerani P, Ghaffari A, Ahmadiani A. Lack of bioequivalence between two aciclovir tablets in healthy subjects. Clin Drug Investig. 2008;28(1):47-53.</citation>
    <PMID>18081360</PMID>
  </results_reference>
  <results_reference>
    <citation>Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, Smiley ML. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993 Dec;54(6):595-605.</citation>
    <PMID>8275615</PMID>
  </results_reference>
  <results_reference>
    <citation>Galgatte UC, Jamdade VR, Aute PP, Chaudhari PD. Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and Canada. Saudi Pharm J. 2014 Nov;22(5):391-402. doi: 10.1016/j.jsps.2013.05.001. Epub 2013 May 31. Review.</citation>
    <PMID>25473327</PMID>
  </results_reference>
  <results_reference>
    <citation>Corrao G, Soranna D, La Vecchia C, Catapano A, Agabiti-Rosei E, Gensini G, Merlino L, Mancia G. Medication persistence and the use of generic and brand-name blood pressure-lowering agents. J Hypertens. 2014 May;32(5):1146-53; discussion 1153. doi: 10.1097/HJH.0000000000000130. Erratum in: J Hypertens. 2015 Jul;33(7):1495. J Hypertens. 2015 Oct;33(10):2181.</citation>
    <PMID>24569417</PMID>
  </results_reference>
  <results_reference>
    <citation>Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008 Dec 3;300(21):2514-26. doi: 10.1001/jama.2008.758. Review.</citation>
    <PMID>19050195</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Indonesian healthy subject</keyword>
  <keyword>Acyclovir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 6, 2021</submitted>
    <returned>November 4, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

